Chipscreen(SH:688321) Zheng Quan Ri Bao·2025-08-19 07:08Core Insights - Micron Biotechnology focuses on developing innovative molecular entities for major diseases with global patent protection and unique clinical effects [1][3] - The company has successfully launched two First-in-Class drugs, Sidaben and Siglitazone, targeting oncology and metabolic diseases, while also addressing unmet clinical needs in neurodegenerative and autoimmune diseases [1][2] Drug Development and Technology - The company utilizes an AI-assisted design and chemical genomics integrated technology platform to enhance drug development processes, improving success rates, accelerating research, and reducing costs [1][3] - Micron Biotechnology has a diverse portfolio of treatment options for complex tumor characteristics, including new generation immune-activating antibody-drug conjugates and small molecule PD-L1 inhibitors [2][4] Clinical Research and Market Potential - The company is conducting clinical studies for its drug Westoroni, which selectively inhibits key proteins related to tumor development, in combination with AG therapy for advanced pancreatic ductal adenocarcinoma [2][4] - The global pancreatic cancer mortality rate is significant, with nearly 470,000 deaths annually, highlighting the urgent need for effective treatments [2] Metabolic Disease Focus - Siglitazone, the world's first PPAR pan-agonist, shows promise in treating diabetes and metabolic-associated fatty liver disease, positioning it as a cornerstone drug for metabolic diseases [4] - The company is also developing First-in-Class small molecules for weight management that do not affect appetite, addressing unmet needs in the obesity treatment landscape [4]